NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today that Ron McClurg will retire as Chief Financial Officer effective June 30, 2026, and will remain as a Senior Advisor through December 31, 2026, to assist with the transition. Chris Volker, the company's current Chief Operating Officer, will assume the role of CFO on a permanent basis. David Wambeke, recently appointed Chief Business Officer, will take over many of Volker's previous responsibilities.
Dave Rosa, CEO of NeuroOne, expressed gratitude for McClurg's contributions over more than five years. "Ron's retirement marks the culmination of a long and successful career, and we are grateful for his leadership, stewardship, and commitment to NeuroOne," Rosa said. "We are also fortunate that he will remain actively involved as a Senior Advisor to help ensure a smooth transition."
Rosa highlighted Volker's qualifications, noting his deep leadership experience across medtech, finance, strategy, and commercial operations. "I believe he is the right person to step into this role as we continue advancing NeuroOne’s technologies and growth strategy," Rosa added.
Volker brings over 25 years of progressive operational and financial leadership, including senior roles at Abbott, Cardiovascular Systems, Inc. (CSI), and St. Jude Medical. At CSI, he served as Vice President & General Manager of International, overseeing international P&L and commercial expansion. Prior to that, he held executive roles at St. Jude Medical, reporting directly to the CFO. He began his career in healthcare investment banking at Dain Rauscher, focusing on financial analysis, M&A, and strategic planning. Volker holds a CFA charterholder designation, an MBA from The Wharton School of the University of Pennsylvania, and a BA from St. John's University.
McClurg commented on his retirement: "It has been a privilege to serve as NeuroOne’s Chief Financial Officer for over five years. I am proud of this team and the benefits our products are providing for patients. I remain fully committed to supporting NeuroOne through this transition."
Volker expressed enthusiasm for his new role: "I am honored to take on the role of Chief Financial Officer. NeuroOne has built strong momentum, both in advancing our product pipeline and commercially, and I look forward to working closely with the team to support strategic, operational, and financial objectives."
NeuroOne is a medical technology company focused on improving surgical care for neurological disorders. The company markets a minimally invasive electrode technology platform with four FDA-cleared product families, including Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System for the brain, and OneRF® Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations and surgical procedures while improving patient outcomes. The company is also engaged in R&D for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
This leadership transition comes as NeuroOne continues to advance its technologies and growth strategy. For more information, visit nmtc1.com.
